Long-term effect of cilostazol on cerebral blood flow in chronic cerebral infarction.
The effect of the oral administration of a new vasodilator, cilostazol (6-[4-(1-cyclohexyl-1H-tetrazol-5-yl) butoxy]-3,4-dihydro-2(1H)-quinolinone, OPC-13013) on cerebral circulation in chronic cerebral infarction was studied by the 133Xenon inhalation method. Mean regional cerebral blood flow (rCBF) was increased in 6 out of 14 cases after 2 weeks of treatment. Hemispheric rCBF was significantly increased in both the affected and non-affected sides (10.8 and 13.4%, respectively) (p less than 0.05) without causing a change in blood pressure.
D000368:Aged; D001393:Azoles / Q000494:pharmacology*; D002544:Cerebral Infarction / Q000503:physiopathology*; D002560:Cerebrovascular Circulation / Q000187:drug effects*; D002908:Chronic Disease; D000077407:Cilostazol; D005260:Female; D005343:Fibrinolytic Agents / Q000494:pharmacology*; D006801:Humans; D008297:Male; D008875:Middle Aged; D013777:Tetrazoles / Q000494:pharmacology*; D014665:Vasodilator Agents / Q000494:pharmacology*; D014980:Xenon Radioisotopes
D001393:Azoles; D005343:Fibrinolytic Agents; D013777:Tetrazoles; D014665:Vasodilator Agents; D014980:Xenon Radioisotopes; D000077407:Cilostazol